Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.
Metrics to compare | ORY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipORYPeersSector | |
---|---|---|---|---|
P/E Ratio | −51.8x | −2.3x | −0.6x | |
PEG Ratio | −4.98 | 0.06 | 0.00 | |
Price/Book | 1.9x | 1.1x | 2.6x | |
Price / LTM Sales | 29.3x | 8.4x | 3.3x | |
Upside (Analyst Target) | 54.3% | 110.3% | 39.0% | |
Fair Value Upside | Unlock | 14.0% | 4.9% | Unlock |